Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Lymphoma 6Hodgkin Disease 4Burkitt Lymphoma 4Sezary Syndrome 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myeloproliferative Disorders 3Mycosis Fungoides 3Multiple Myeloma 3Lymphoproliferative Disorders 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Immunoblastic Lymphadenopathy 3Primary Myelofibrosis 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Pdgfra-Associated Chronic Eosinophilic Leukemia 2Ovarian Neoplasms 2Myelodysplastic-Myeloproliferative Diseases 2Melanoma 2Lymphoma, Large-Cell, Anaplastic 2Leukemia, Neutrophilic, Chronic 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2

Interventions

Cyclophosphamide 101Etoposide 60Carboplatin 55Vincristine 51Filgrastim 49Topotecan 44Temozolomide 44Melphalan 44Isotretinoin 44Doxorubicin 44Irinotecan 42Cisplatin 353-Iodobenzylguanidine 34Peripheral Blood Stem Cell Transplantation 31dinutuximab 30Granulocyte Colony-Stimulating Factor 30Radiotherapy 29sargramostim 28Granulocyte-Macrophage Colony-Stimulating Factor 25Busulfan 22Magnetic Resonance Spectroscopy 19aldesleukin 18Thiotepa 18fludarabine 17Interleukin-2 17humanized 3F8 anti-GD2 monoclonal antibody 16etoposide phosphate 16naxitamab 15Ifosfamide 15Biopsy 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroblastoma × Ganciclovir × Clear all
NCT00006480 2010-09-21

Biological Therapy and Gene Therapy in Treating Children With Recurrent or Refractory Neuroblastoma

Fred Hutchinson Cancer Center

Phase 1 Completed
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡